Mean change from baseline in best-corrected visual acuity (BCVA) at each visit in the BAMBOO and CYPRESS studies. The primary endpoint was at week 16. Green and orange arrows indicate treatment with abicipar and ranibizumab, respectively. Missing data were imputed with the last observation carried forward. Errors bars indicate standard error of the mean.